CIITA and cancer: Silencing the expression of CIITA, the master regulator of MHC Class II, in cancer cells that express MHC II in vivo blunted the response to anti-PD-1, whereas expressing CIITA in resistant cells sensitized tumors to anti-PD-1 therapy [96].